Ethics approval

JG Jiafen Gong
GH Gengming He
CW Cheng Wang
CB Claire Bartlett
NP Naim Panjwani
SM Scott Mastromatteo
FL Fan Lin
KK Katherine Keenan
JA Julie Avolio
AH Anat Halevy
MS Michelle Shaw
ME Mohsen Esmaeili
GC Guillaume Côté-Maurais
DA Damien Adam
SB Stéphanie Bégin
CB Candice Bjornson
MC Mark Chilvers
JR Joe Reisman
AP April Price
MP Michael Parkins
RW Richard van Wylick
YB Yves Berthiaume
LB Lara Bilodeau
DM Dimas Mateos-Corral
DH Daniel Hughes
MS Mary J. Smith
NM Nancy Morrison
JB Janna Brusky
ET Elizabeth Tullis
AS Anne L. Stephenson
BQ Bradley S. Quon
PW Pearce Wilcox
WL Winnie M. Leung
MS Melinda Solomon
LS Lei Sun
EB Emmanuelle Brochiero
TM Theo J. Moraes
TG Tanja Gonska
FR Felix Ratjen
JR Johanna M. Rommens
LS Lisa J. Strug
ask Ask a question
Favorite

The Canadian CF Gene Modifier Study (CGMS) was approved by the Research Ethics Board of the Hospital for Sick Children (# 0020020214 from 2012 to 2019 and #1000065760 from 2019-present) and all participating sub-sites. Written informed consent was obtained from all participants or parents/guardians/substitute decision makers prior to inclusion in the study. The CGMS is also approved by the Research Ethics Board of the Hospital for Sick Children for the usage of public and external data. The US PROSPECT study provides data from a clinical trial registered at https://clinicaltrial.gov, identifier NCT02477319, and we obtained these data through application to the US CFF at https://www.cff.org/researchers/cf-foundation-biorepository.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A